CN1258293A - 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 - Google Patents
取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 Download PDFInfo
- Publication number
- CN1258293A CN1258293A CN98805614A CN98805614A CN1258293A CN 1258293 A CN1258293 A CN 1258293A CN 98805614 A CN98805614 A CN 98805614A CN 98805614 A CN98805614 A CN 98805614A CN 1258293 A CN1258293 A CN 1258293A
- Authority
- CN
- China
- Prior art keywords
- atom
- hydrogen atom
- methyl
- alkyl
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 14
- FPNJYPLJTAYAMP-UHFFFAOYSA-N 7a-(2,6-dioxopiperidin-3-yl)-3ah-isoindole-1,3-dione Chemical class C1=CC=CC2C(=O)NC(=O)C21C1CCC(=O)NC1=O FPNJYPLJTAYAMP-UHFFFAOYSA-N 0.000 title abstract 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 46
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 32
- -1 tetramethylene, pentamethylene, hexamethylene Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 51
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 abstract 1
- KDHAQQFLGBZQCF-UHFFFAOYSA-N 3-methyl-3-(4,5,6,7-tetrafluoro-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical group C1C(C(=C(F)C(F)=C2F)F)=C2C(=O)N1C1(C)CCC(=O)NC1=O KDHAQQFLGBZQCF-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 25
- 239000007787 solid Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000725303 Human immunodeficiency virus Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229960002989 glutamic acid Drugs 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- PWDAMYOWDVSLPY-UHFFFAOYSA-N 2,3-dihydro-1h-isoindol-1-amine Chemical compound C1=CC=C2C(N)NCC2=C1 PWDAMYOWDVSLPY-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 206010039361 Sacroiliitis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- PLOAYYLMSOWRAI-UMJHXOGRSA-N (4s)-5-amino-2-methyl-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound OC(=O)C(C)C[C@@H](C(N)=O)NC(=O)OCC1=CC=CC=C1 PLOAYYLMSOWRAI-UMJHXOGRSA-N 0.000 description 2
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 241000219161 Theobroma Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- IJOQQDNARPXNSY-BKLSDQPFSA-N (4S)-4,5-diamino-2-methyl-5-oxopentanoic acid Chemical compound CC(C[C@H](N)C(=O)N)C(=O)O IJOQQDNARPXNSY-BKLSDQPFSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- DRMYLINAGHHBNG-UHFFFAOYSA-N 2-oxo-3h-furan-4-carboxylic acid Chemical compound OC(=O)C1=COC(=O)C1 DRMYLINAGHHBNG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101100229963 Drosophila melanogaster grau gene Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- ORYOIBJWFDNIPD-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O ORYOIBJWFDNIPD-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明涉及可降低哺乳动物体内TNFα水平的取代的2－(2,6－二氧哌啶－3－基)邻苯二甲酰亚胺和1－氧－2－(2,6－二氧哌啶－3－基)异二氢吲哚,其中典型的例子是1－氧－2－(2,6－二氧－3－甲基哌啶－3－基)－4,5,6,7－四氟异二氢吲哚。
Description
本发明涉及取代的2-(2，6-二氧哌啶-3-基)-邻苯二甲酰亚胺和取代的2-(2，6-二氧哌啶-3-基)-1-氧异二氢吲哚，通过服用这类化合物来降低哺乳动物体内肿瘤坏死因子α水平、治疗炎症和自身免疫疾病的方法，以及这样的衍生物的药物组合物。
发明的背景
肿瘤坏死因子α(TNFα)是主要由单核巨噬细胞对各种免疫刺激剂的应答而释放的细胞因子。将其施加于动物和人时，可引起炎症、发热、心血管影响、出血、凝血及类似于急性感染和休克状态所见的急性反应。因此，在很多疾病状态均可伴有TNFα产生过量或失控。这些疾病包括内毒素血症和/或中毒性休克综合征{Tracey等，Nature 330，662-664(1987)和Hinshaw等，Circ.Shock30，279-292(1990)}；恶病质{Dezube等，Lancet，335(8690)，662(1990)}和成人呼吸窘迫综合征，其中从患者肺呼出气中检出TNFα的浓度超出12,000pg/mL{Millar等，Lancet 2(8665)，712-714(1989)}。重组TNFα全身输注也导致ARDS中所见的改变{Ferrai-Baliviera等，Arch.Surg.124(12)，1400-1405(1989)}。
TNFα似乎涉及骨吸收疾病，包括关节炎。当发作时，白细胞会产生骨吸收，资料提示TNFα与其发作有关{Bertolini等，Nature 319，516-518(1986)和Johnson等，Endocrinology 124(3)，1424-1427(1989).}在体内、外试验中还证明，TNFα通过刺激破骨细胞形成和激活，同时抑制成骨细胞的功能，从而刺激骨吸收和抑制骨生成。尽管TNFα可能涉及很多骨吸收性疾病，包括关节炎，但最令人非相信不可的与疾病的联系是肿瘤或宿主组织TNFα的产生与伴有高钙血症的恶性程度之间的关联{Calci.Tissue Int.(US)46(Suppl.)，S3-10(1990)}。急性同种异型骨髓移植后，在移植物对宿主反应中，主要并发症伴有血清TNFα水平的提高{Holler等，Blood，75(4)，1011-1016(1990)}。
脑疟疾是伴有TNFα高血浓度的致死性超急性神经综合征，是疟疾患者中出现的最严重的并发症。血清TNFα水平与疟疾急性发作患者疾病的严重程度和预后直接相关{Grau等N.Engl.J.Med.320(24)，1586-1591(1989)}。
已知巨噬细胞诱导的血管生成由TNFα介导。Leibovich等{Nature，329，630-632(1987)}在大鼠角膜和发育中的小鸡绒毛尿囊膜上证明，很低剂量的TNFα即引起体内毛细血管的形成，提示TNFα在炎症、伤口修复和肿瘤生长上是诱导血管生成的因素。TNFα的产生还与癌性疾病、特别是诱发肿瘤相关联{Ching等，Brit.J.Cancer，(1955)72，339-343和Koch，Progress inMedicinal Chemistry，22，166-242(1985)}。
TNFα还在慢性肺部炎症性疾病方面起作用。硅石颗粒的沉积导致矽肺，一种纤维变性反应引起的进行性呼吸衰竭疾病。抗TNFα抗体完全阻断硅石引起的小鼠肺纤维变性{Pignet等，Nature，344：245-247(1990)}。在硅石和石棉沉着病导致纤维变性的动物模型上证明，血清和分离出的巨噬细胞中有高水平TNFα的产生{Bissonnette等，Inflammation 13(3)，329-339(1989)}。还有人发现，从肺类肉瘤病患者取出的肺泡巨噬细胞与从正常供体而来的巨噬细胞相比，该疾病自发性释放大量TNFα{Baughman等，J.Lab.Clin.Med.115(1)，36-42(1990)}。
TNFα还与再灌注(称作再灌注损伤)后的炎症反应有关，是缺血流后组织损伤的主要原因{Vedder等，PNAS 87，2643-2646(1990)}。TNFα还能改变内皮细胞的性质，具有各种促凝血活性，如产生组织因子促凝血活性提高和抗凝血蛋白C途径的抑制，以及下调凝血调节蛋白的表达{Sherry等，J.Cell Biol.107，1269-1277(1988)}。TNFα具有促炎症活性，该活性与TNFα的早期产生(在炎症初期)使其更象是几种重要疾病(包括但不限于心肌梗塞、卒中和循环休克)中组织损伤的介质。特别重要的可以是TNFα诱导的粘合分子如细胞间粘合分子(ICAM)或内皮白细胞粘合分子(ELAM)在内皮细胞上的表达{Munro等，Am.J.Path.135(1)，121-132(1989)}。
用抗TNFα单克隆抗体封闭TNFα已被证明对类风湿性关节炎{Elliot等，Int.J.Pharmac.1995 17(2)，141-145}和Crohn’s病{von Dullemen等，Gastroenterology，1995 109(1)，129-135}有益。
此外，现已知道，TNFα是轮状病毒复制包括HIV-1激活的潜在激活剂{Duh等，Proc.Nat.Acad.Sci.86，5974-5978(1989)；Poll等，Proc.Nat.Acad.Sci.87，782-785(1990)；Monto等，Blood 79，2670(1990)；Clouse等，J.Immunol.142，431-438(1989)；Poll等，AIDS Res.Hum.Retrovirus，191-197(1992)}。AIDS由人免疫缺陷病毒(HIV)感染T淋巴细胞而引起。至少有三种类型或三株HIV已被鉴定出来，即HIV-1，HIV-2和HIV-3。作为HIV感染的结果，T细胞介导的免疫受损，受感染的个体出现严重的机会感染和/或异常新生物。HIV进入T淋巴细胞需要激活T淋巴细胞。其他病毒(如HIV-1和HIV-2)在T细胞激活后感染T淋巴细胞，这些病毒蛋白的表达和/或复制由这种T细胞激活所介导或维持。一旦被激活的T淋巴细胞感染了HIV，该T淋巴细胞必须继续维持激活状态，以使HIV基因表达和/或HIV复制。细胞因子，特别是TNFα，通过在维持T淋巴细胞活化上起作用而参与活化T细胞介导的HIV蛋白表达和/或病毒复制。因此，在HIV感染的个体上，诸如通过阻止或抑制细胞因子(值得注意的是TNFα)的产生来干扰细胞因子的活性，有助于限制HIV感染引起的淋巴细胞的维持。
单核细胞、巨噬细胞和相关的细胞(如枯否氏细胞和胶质细胞)也参与HIV感染的维持。这些细胞象T细胞一样，是病毒复制的靶细胞，病毒复制的水平依赖于细胞的激活状态，{Rosenberg等，The Immunopathogenesis of HIVInfection，Advances in Immunology，57(1989)}。细胞因子(如TNFα)已被证明在单核细胞和/或巨噬细胞上激活HIV复制{Poli等，Proc.Natl.Acad.Sci.，87，782-784(1990)}，因此，阻止或抑制细胞因子的产生或其活性有助于限制HIV侵入T细胞。另外的研究将TNFα鉴定为体外HIV激活的共同因子，并提供了细胞的胞质中已发现的核调节蛋白起作用的明确的作用机制(Osborn等，PNAS 86 2336-2340)。该证据揭示，TNFα合成的减少通过降低转录从而减少病毒产生，可在HIV感染中具有抗病毒效应。
潜伏在T细胞和巨噬细胞株内的HIV的AIDS病毒复制可被TNFα诱导{Folks等，PNAS 86，2365-2368(1989)}。有人提出，该病毒诱导活性的分子机理系通过TNFα激活细胞胞质中所见基因调节蛋白(NFκB)的能力，促进HIV结合于病毒调节基因序列(LTR)而进行复制{Osborn等，PNAS 86：2336-2340(1989)}。有人提出，伴有恶病质的AIDS中的TNFα系血清TNFα的提高及患者外周血液单核细胞中高水平自发性TNFα产生所致{Wright等，J.Immunol.141(1).99-104(1988)}。如上面提到的类似的理由，TNFα参与其他病毒感染{如细胞肥大包涵体病毒(CMV)、流感病毒、腺病毒和疱疹病毒族)的各种作用。
核因子κB(NFκB)是多效转录激活剂(Lenardo等，Cell 1989，58，227-29)。NFκB作为转录激活剂参与各种疾病和炎症状态，被认为能调节细胞因子(包括但不限于TNFα)的水平，并且也是HIV转录的激活剂{Dbaibo等，J.Biol.Chem.1993，17762-66；Duh等，Proc，.Natl.Acad.Sci.1989，86，5974-78；Bachelerie等，Nature 1991，350，709-12；Boswas等，J.Acquired ImmuneDeficiency Syndrome 1993，6，778-786；Suzuki等，Biochem.And Biophys.Res.Comm.1993.193.277-83；SuZuki等，Biochem.And Biophys.Res Comm.1992.189，1709-15；Suzuki等，Biochem.Mol.Bio.Int.1993，31(4)，693-700；Shakhov等，Proc.Natl.Acad.Sci.USA 1990，171，35-47；和Staal等，Proc.Natl.Acad.Sci.USA 1990，87，9943-47)。因此，抑制NFκB结合可调节细胞因子基因的转录，通过这一调节和其他机制，用于抑制众多疾病。本说明书中描述的化合物可抑制核内NFκB的作用，从而用于治疗各种疾病，包括但不限于类风湿性关节炎、类风湿性脊椎炎、骨关节炎、其他关节炎、脓毒性休克、脓毒症、内毒素性体克、移植物抗宿主疾病、消耗性疾病、克罗恩氏病、炎性肠疾病、溃疡性结肠炎、多发性硬化、全身性红斑狼疮、麻风中的ENL、HIV、AIDS及AIDS中的机会感染。TNFα和NTκB水平受逆反馈环的支配。如上所述，本发明的化合物对TNFα和NFκB的水平均有影响。
很多细胞功能由3’，5’-环-磷酸腺苷(cAMP)水平介导。这些细胞功能可造成炎性状态和包括哮喘、炎症和其他病状的疾病{Lowe和Cheng，Drugs ofthe Future，17(9)，799-807，1992)。现已证明，炎性白细胞中cAMP的升高抑制这些细胞的活性和炎性介质(包括TNFα和NFκB)的随后释放。cAMP水平的升高还导致呼吸道平滑肌的松驰。
因此，降低TNFα水平和/或提高cAMP水平构成治疗很多炎症、感染性、免疫学或恶性疾病的有价值的治疗战略。这些疾病包括但不限于脓毒性休克、脓毒症、内毒素性休克、血液动力学休克和脓毒综合征、梗塞后再灌注损伤、疟疾、分支杆菌感染、脑脊膜炎、牛皮癣、充血性心力衰竭、纤维化疾病、恶病质、移植物排斥、癌症、自身免疫性疾病、AIDS的机会性感染、类风湿性关节炎、类风湿性脊椎炎、骨关节炎、其他关节炎病症、克罗恩氏病、溃疡性结肠炎、多发性硬化、全身红斑狼疮、麻风中的ENL、放射损伤和高氧性肺泡损伤。关于抑制TNFα效应的以往的努力涉及从利用地塞米松和强的松龙之类甾体药物到使用多克隆和单克隆抗体{Beutler等，Science 234，470-474(1985)；WO 92/11383}。
详细描述
本发明基于这样的发现，即本说明书较完整描述的某些种类的非多肽类化合物可降低TNF α的水平。
本发明特别是以下通式I所示化合物其中：
X和Y中一个是C＝O，X和Y中另一个是C＝O或CH2：
(i)R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，或(ii)R1、R2、R3和R4之一为-NHR5，其余的R1、R2、R3和R4为氢原子；
R5为氢原子或1-8个碳原子的烷基；
R6为氢原子、1-8个碳原子的烷基、苄基(benzo)、氯原子或氟原子；
R7为间亚苯基或对亚苯基或-(CnH2n)-，其中的n为0-4；
R8和R9各自独立地为氢原子或1-8个碳原子的烷基，或者R8和R9一起表示四亚甲基、l，5-亚戊基、1，6-亚己基或-CH2CH2XCH2CH2-，其中的X为-O-、-S-或-NH-；
R10为氢原子、1-8个碳原子的烷基或苯基；
(b)含有一个可被质子化的氮原子的所述化合物的酸加成盐。
第一组较佳的化合物是通式I中至少R1、R2、R3、R4和R6之一不为氢原子的化合物。其中，更好的是R1、R2、R3、R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，R6为氢原子、甲基、乙基或丙基，R8和R9各自独立地为氢原子或甲基，R10为氢原子的一组化合物。这些化合物中更好的是R7为间亚苯基或对亚苯基的化合物，或R7为-(CnH2n)-的化合物，其中的n为0-4。
第二组较佳的化合物是通式I中R1、R2、R3和R4之一为-NH2，其余的R1、R2、R3和R4为氢原子，R6为氢原子、甲基、乙基或丙基，R8和R9各自独立地为氢原子或甲基，R10为氢原子的一组化合物。这些化合物中更好的是R7为间亚苯基或对亚苯基的化合物，或R7为-(CnH2n)-的化合物，其中的n为0-4。
术语“烷基”指含有1-8个碳原子的直链或支链一价饱和烃链。这样的烷基的代表为甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基和叔丁基。烷氧基指通过醚氧原子键合到分子其余部分的烷基。这样的烷氧基的代表为甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、仲丁氧基和叔丁氧基。R1、R2、R3和R4以氯、氟、甲基或甲氧基为佳。
在有资格的专门医师指导下，式I化合物被用来抑制TNFα的不期望有的作用。这些化合物可单独地或与其它治疗剂(包括抗生素、甾类化合物等)合用，给需要治疗的哺乳动物口服给药、直肠给药或胃肠外给药。
本发明的化合物还可局部用于由过量TNFα的产生分别介导或加剧的局部病症的治疗或预防，例如病毒感染(如由疱疹病毒引起的感染)或病毒性结膜炎、牛皮癣、特应性皮炎等。
这些化合物还可用于需要阻止或抑制TNFα产生的人以外的哺乳动物的兽医治疗。在动物上处理(治疗或预防)的TNFα介导的疾病包括上面所述的那些病症，但特别是病毒感染。其例子包括猫免疫缺陷病毒、马感染性贫血病毒、羊关节炎病毒、绵羊脱髓鞘性脑白质炎病毒和梅迪(maedi)病毒，以及其它慢病毒(lentiviruses)。
通过甲醛和通式IIA
表示的中间体的起始反应可制备上述化合物。其中，X和Y的含义如上所述；R1、R2、R3和R4各自独立地表示卤原子、1-4个碳原子的烷基、1-4个碳原子的烷氧基或(ii)R1、R2、R3和R4之一为硝基或被保护的氨基，其余的R1、R2、R3和R4为氢原子；R6为氢原子、1-8个碳原子的烷基、苄基(benzo)、氯原子或氟原子。
然后，利用公知的方法使所得的通式II表示的N-羟甲基中间体和通式IV表示的羧酸衍生物进行偶合反应，其中的Hal表示氯原子、溴原子或碘原子等反应性卤原子。
此处所用的保护基指在最终的治疗化合物中一般见不到但在合成的某个阶段为了保护化学操作过程中可能改变的基团而有意引入的基团。在合成的较后阶段除去这种保护基，带有这种保护基的化合物基本上作为化学中间体有其重要性(尽管有些衍生物也显示生物活性)。因此，保护基的确切结构并不严格要求。在大量标准著作中，描述了用于形成和除去保护基的种种反应，这些著作包括例如“Protective Groups in Organic Chemistry”，Plemun Press，London and New York，1973；Greene，Th.W.″Protective Groups in OrganicSynthesis“，Wiley，New York，1981；″The Peptides″，Vol.I，Schroderand Lubke，Academic Press，London and New York，1965；″Methoden derOrganischen Chemie″，Houben-Weyl，4th Edition，Vol.15/I，Georg ThiemeVerlag，Stuttgart 1974，它们揭示的内容结合于此作为参考。
氨基可利用酰基以酰胺的形式保护起来，该酰基可在温和条件下选择性地除去，特别是苄氧基羰基、甲酰基或在羰基的1-位或α-位上有支链的低级烷酰基，特别是叔烷酰基，如三甲基乙酰基，在羰基的α位上被取代的低级烷酰基，如三氟乙酰基。
偶合剂包括二环己基碳二亚胺和N，N’-羰基二咪唑等试剂。
偶合反应后，利用常规方法使通式V表示的化合物胺化，例如，在碘化钠的存在下使该化合物与胺发生反应。
或者，使通式III表示的化合物与通式IVA表示的被保护的氨基羧酸进行反应，
其中的Z表示被保护的氨基。
偶合反应后，氨基保护基团Z被除去。
前述反应中，如果R1、R2、R3和R4之一为硝基，则通过催化氢化作用可将硝基转变为氨基；如果R1、R2、R3和R4之一为被保护的氨基，则保护基团被分解获得R1、R2、R3和R4之一为氨基的相应化合物。
除了作为中间体之外，通式IIA表示的某些其他化合物自身就具备降低哺乳动物体内肿瘤坏死因子α的生物学活性，这些化合物由通式IIB表示，
其中，X和Y之一为C＝O，另一为C＝O或CH2；(i)R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基、1-4个碳原子的烷氧基或(ii)R1、R2、R3和R4之一为-NHR5，其余的R1、R2、R3和R4为氢原子；R5为氢原子或1-8个碳原子的烷基或CO-R7-CH(R10)NR8R9，其中R7、R8、R9和R10如前所述；R6为1-8个碳原子的烷基、苄基(benzo)、氯原子或氟原子。
某些通式IIA表示的中间体在相关申请Serial Nos.08/690,258和08/701,494中被揭示，这些被揭示的中间体在此供本发明参考。另外，在三乙胺等酸性接受体存在下，使R1、R2、R3和R4适当取代的邻溴甲基苯甲酸烷酯和α-R6-取代的α-氨基戊二酰亚胺的盐反应也能够获得X和Y之一为C＝O，另一为CH2的化合物。
在乙酸或乙酸钠存在下，使R1、R2、R3和R4适当取代的邻苯二甲酸酐与α-R6-取代的α-氨基戊二酰亚胺的盐反应也可制得X和Y都为C＝O的通式IIA表示的化合物。
使氨基被保护的α-R6-取代的谷氨酰胺进行环化反应就可制得用于前述反应的α-R6-取代的α-氨基戊二酰亚胺的盐。例如，上述环化反应可在二甲基氨基吡啶等酸性接受体的存在下，使上述谷氨酰胺与N，N’-羰基二咪唑反应而进行。反应结束后，利用适当的方法可除去保护基团。例如，如果保护基团为N-苄氧基羰基，则利用催化氢化反应可除去该基团。
使α-R6-取代的谷氨酸与乙酸酐进行反应获得α-R6-取代的谷氨酸酐，然后，使氨基被保护的α-R6-取代的谷氨酸酐与氨发生反应就可获得α-R6-取代的谷氨酰胺。
通式I和IIB的化合物具有手性中心，可以旋光异构体的形式存在。当具有2个手性中心时，这些异构体的外消旋体及其各自的异构体，以及非对映异构体均在本发明的范围内。外消旋体可直接使用，或可用物理方法，如通过使用手性吸附剂的色谱法将其分离成各个异构体。或者，可以手性形式制备各个异构体，或用化学方法，通过与手性酸成盐从混合物中分离各个异构体，例如，10-樟脑磺酸、樟脑酸、α-溴代樟脑酸、甲氧基乙酸、酒石酸、二乙酰基酒石酸、苹果酸、吡啶烷酮-5-羧酸等的各个对映体，然后将拆分开的一个碱或两个碱均游离出来，可任意地重复此过程，以获得基本上没有另一个的任何一个或两个各自的异体构，即光学纯度＞95％的形式。
本发明还涉及通式I和IIB化合物的生理学上可接受的无毒酸加成盐。这样的盐包括从有机和无机酸生成的盐，例如(但不限于)，盐酸、氢溴酸。磷酸、硫酸、甲磺酸、乙酸、酒石酸、乳酸、琥珀酸、柠檬酸、苹果酸、马来酸、山梨酸、阿康酸、水杨酸、苯二甲酸、双羟萘酸、庚酸等。
口服剂型包括片剂、胶囊剂、糖锭剂(dragees)，及类似形状的压制的药物剂型，每单位剂量包含1-100mg药物。可用含20-100mg/ml的等渗盐水溶液作为非胃肠道给药，包括肌肉、鞘内、静脉内和动脉内途径给药。使用从常规载体如可可脂制成的栓剂可进行直肠给药。
药物组合物包括一种或几种通式I、IIB的化合物，以及至少一种药学上可接受的载体、稀释剂或赋形剂。在制备这些组合物时，通常将活性成分与赋形剂混合，或用赋形剂稀释，或包在可以胶囊或药囊形式存在的载体中。当赋形剂起稀释剂作用时，它可以是固体、半固体或液体材料作为赋形剂、载体或活性成分的介质。因此，组合物可以是片剂、丸剂、粉剂、酏剂、混悬剂、乳剂、溶液剂、糖浆剂、软和硬明胶胶囊、栓剂、灭菌可注射溶液和灭菌包装粉剂。合适的赋形剂的例子包括乳糖、葡萄糖、蔗糖、山梨醇、甘露醇。淀粉、阿拉伯胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆和甲基纤维素，制剂还可包括润滑剂(如滑石粉、硬脂酸镁和矿物油)，湿润剂，乳化剂和悬浮剂，防腐剂(如羟基苯甲酸甲酯和丙酯)，甜味剂或矫味剂。
组合物以制成单位剂量形式为宜，即适合作为单一剂量的物理学上分开的单位，或准备以一次或多次剂量方案对人和其他哺乳动物投药的单一剂量的预定部分，每一单位包含为产生所期望的治疗效应而计算出预定量的活性物质，以及合适的药剂学赋形剂。采用本领域熟知的方法，可将组合物制成给患者投药后能立即、持续或缓慢释放活性成分的制剂。
口服剂型包括片剂、胶囊剂、糖锭剂(dragees)，及类似形状的压缩的药物剂型，每单位剂量包含1-100mg药物。可用含20-100mg/ml的等渗盐水溶液作为非胃肠道给药，包括肌肉、鞘内、静脉和动脉途径给药。使用从常规载体如可可脂制成的栓剂可进行直肠给药。
药物组合物包括一种或几种通式I的化合物，以及至少一种药学上可接受的载体、稀释剂或赋形剂。在制备这些组合物时，通常将活性成分与赋形剂混合，或用赋形剂稀释，或包在可以胶囊或药囊形式存在的载体中。当赋形剂起稀释剂作用时，它可以是固体、半固体或液体材料作为赋形剂、载体或活性成分的介质。因此，组合物可以是片剂、丸剂、粉剂、酏剂、混悬剂、乳剂、溶液剂、糖浆剂、软和硬明胶胶囊、栓剂、灭菌可注射溶液和灭菌包装粉剂。合适的赋形剂的例子包括乳糖、葡萄糖、蔗糖、山梨醇、甘露醇。淀粉、阿拉伯胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆和甲基纤维素，制剂还可包括润滑剂(如滑石粉、硬脂酸镁和矿物油)，湿润剂，乳化剂和悬浮剂，防腐剂(如羟基苯甲酸甲酯和丙酯)，甜味剂或矫味剂。
组合物以制成单位剂量形式为宜，即适合作为单一剂量的物理学上分开的单位，或准备以一次或多次剂量方案对人和其他哺乳动物投药的单一剂量的预定部分，每一单位包含为产生所期望的治疗效应而计算出预定量的活性物质，以及合适的药剂学赋形剂。采用本领域熟知的方法，可将组合物制成给患者投药后能立即持续或缓慢释放活性成分的制剂。
下面的实施例将进一步作为本发明实质的典型，但不应看作对其范围的限制，该范围只能由所附的权利要求来限定。
实施例1
N-苄氧基羰基-α-甲基-谷氨酸
在0～5℃的温度及搅拌状态下，在α-甲基-D，L-谷氨酸(10g，62mmol)的2N氢氧化钠(62mL)中加入氯甲酸苄酯(12.7g，74.4mmol)，历时30分钟。加料结束后在室温下搅拌反应混合液，历时3小时。在搅拌过程中滴加2N氢氧化钠(33mL)将反应液的pH值控制在11。然后用乙醚(60ml)萃取反应液。在冰浴中冷却水层，用4N盐酸(34mL)酸化，将pH值调为1。接着，用乙酸乙酯(3×100mL)萃取反应液，再用盐水(60mL)洗涤合并后的乙酸乙酯提取液，用硫酸镁干燥。真空除去溶剂，获得15.2g(83％)为油状的N-苄氧基羰基-α-甲基-谷氨酸。
1H NMR(CDCl3)
δ8.73(m，5H)，5.77(b，1H)，5.09(s，2H)，2.45-2.27(m，4H)，2.0(s，3H)
与上述同样操作，由α-乙基-D，L-谷氨酸和α-丙基-D，L-谷氨酸可分别获得N-苄氧基羰基-α-乙基-谷氨酸和N-苄氧基羰基-α-丙基-谷氨酸。
实施例2
N-苄氧基羰基-α-甲基-谷氨酸酐
在氮气氛围中搅拌加热回流N-苄氧基羰基-α-甲基-谷氨酸(15g，51mmol)和乙酸酐(65mL)的混合液，历时30分钟。使反应液冷却至室温后，真空浓缩，获得油状N-苄基羰基-α-甲基-谷氨酸酐(15.7g)，它不用进一步精制就可直接用于下一步反应。
1H NMR(CDCl3)
δ7.44-7.26(m，5H)，5.32-5.30(m，2H)，5.11(s，1H)，2.69-2.61(m，2H)，2.40-2.30(m，2H)，1.68(s，3H)
与上述同样操作，由N-苄氧基羰基-α-乙基-谷氨酸和N-苄氧基羰基-α-丙基-谷氨酸可分别获得N-苄基羰基-α-乙基-谷氨酸酐和N-苄基羰基-α-丙基-谷氨酸酐。
实施例3
N-苄氧基羰基-α-甲基-异谷氨酰胺
在冰水浴中冷却搅拌下的N-苄基羰基-α-甲基-谷氨酸酐(14.2g，51.5mmol)的二氯甲烷(100mL)溶液，然后在经过冷却的溶液中吹入氨气，历时2小时。在室温下搅拌反应液，历时17小时，再用水(2×50mL)萃取。接着在冰水浴中冷却合并的水层，用4N盐酸(32mL)酸化，将pH值调整到1，再用乙酸乙酯(3×80mL)萃取反应液，然后用盐水(60mL)对合并的乙酸乙酯提取液进行洗涤，并用硫酸镁干燥。真空除去溶剂，获得11.5g N-苄氧基羰基-α-氨基α-甲基-异谷氨酰胺。
1H NMR(CDCl3/DMSO)
δ7.35(m，5H)，7.01(s，1H)，6.87(s，1H)，6.29(s，1H)，5.04(s，2H)，2.24-1.88(m，4H)，1.53(s，3H)
与上述同样操作，由N-苄基羰基-α-乙基-谷氨酸酐和N-苄基羰基-α-丙基-谷氨酸酐可分别获得N-苄氧基羰基-α-氨基-α-乙基-异谷氨酰胺和N-苄氧基羰基-α-氨基-α-丙基-异谷氨酰胺。
实施例4
N-苄氧基羰基-α-氨基-α-甲基戊二酰亚胺
在氮气氛围中，使搅拌下的N-苄氧基羰基-α-甲基-异谷氨酰胺(4.60g，15.6mmol)、1，1’-羰基二咪唑(2.80g，17.1mmol)、4-二甲基氨基吡啶(0.05g)的四氢呋喃(50mL)溶液加热回流17小时，然后真空浓缩反应液，获得油状物，将该油状物混合入水(50mL)中，历时1小时。过滤所得的悬浮液，用水洗涤固状物，自然干燥后，获得3.8g为白色固体的粗品。再用快速层析法(二氯甲烷∶乙酸乙酯＝8∶2)对粗品进行精制，获得2.3g(50％)为白色固体的N-苄氧基羰基-α-氨基-α-甲基戊二酰亚胺。
熔点：150.5-152.5℃
1H NMR(CDCl3)
δ8.21(s，1H)，7.34(s，5H)，5.59(s，1H)，5.08(s，2H)，2.74-2.57(m，3H)，2.28-2.25(m，1H)，1.54(s，3H)
13C NMR(CDCl3)
δ174.06，171.56，154.68，135.88，128.06，127.69，127.65，66.15，54.79，29.14，28.70，21.98
HPLC：Waters Nova-Pak C18柱，4微米，3.9×150mm，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，7.56分钟(100％)
分析计算值(C14H16N2O4)：
C， 60.86， H， 5.84， N， 10.14
实测值：
C， 60.88， H， 5.72， N， 10.07
与上述同样操作，由N-苄氧基羰基-α-氨基-α-乙基-异谷氨酰胺和N-苄氧基羰基-α-氨基-α-丙基-异谷氨酰胺可分别获得N-苄氧基羰基-α-氨基-α-乙基-戊二酰亚胺和N-苄氧基羰基-α-氨基-α-丙基-戊二酰亚胺。
实施例5
盐酸α-氨基-α-甲基-戊二酰亚胺
在温热条件下将N-苄氧基羰基-α-氨基-α-甲基戊二酰亚胺(2.3g，8.3mmol)溶于乙醇(200mL)中，然后冷却至室温，在该溶液中加入4N盐酸(3mL)和10％Pd/C(0.4g)。接着在50psi的氢气压力下，在帕尔仪器中进行氢化反应，历时3小时。然后在反应液中加水(50mL)，使产物溶解，再用经过水洗(50mL)的硅藻土过滤反应液，真空浓缩滤液，获得固体残渣。将该固状物混合入乙醇(20mL)中，历时30分钟。过滤所得淤浆，获得1.38g(93％)为白色固体的盐酸α-氨基-α-甲基-戊二酰亚胺。
1H NMR(DMSO-d6)
δ11.25(s，1H)，8.92(s，3H)，2.84-2.51(m，2H)，2.35-2.09(m，2H)，1.53(s，3H)
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，1.03分钟(94.6％)
与上述同样操作，由N-苄氧基羰基-α-氨基-α-乙基-戊二酰亚胺和N-苄氧基羰基-α-氨基-α-丙基-戊二酰亚胺可分别获得盐酸α-氨基-α-乙基-戊二酰亚胺和盐酸α-氨基-α-丙基-戊二酰亚胺。
实施例6
3-(3-硝基苯二甲酰亚氨基)-3-甲基哌啶-2，6-二酮
在氮气氛围中，将搅拌下的盐酸α-氨基-α-甲基-戊二酰亚胺(1.2g，6.7mmol)、3-硝基邻苯二甲酸酐(1.3g，6.7mmol)、乙酸钠(0.6g，7.4mmol)的乙酸(30mL)溶液加热回流6小时。然后冷却反应液，真空浓缩，将所得固状物混合入水(30mL)和二氯甲烷(30mL)中，历时30分钟。过滤悬浮液，用二氯甲烷洗涤所得固体，真空干燥(60℃，＜1mm)，获得1.44g(68％)为灰白色固体的3-(3-硝基苯二甲酰亚氨基)-3-甲基哌啶-2，6-二酮。
熔点：265-266.5℃
1H NMR(DMSO-d6)
δ11.05(s，1H)，8.31(dd，J＝1.1，7.9Hz，1H)，8.16-8.03(m，2H)，2.67-2.49(m，3H)，2.08-2.02(m，1H)，1.88(s，3H)
13C NMR(DMSO-d6)
δ172.20，171.71，165.89，163.30，144.19，136.43，133.04，128.49，126.77，122.25，59.22，28.87，28.49，21.04
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，7.38分钟(98％)
分析计算值(C14H11N3O6)：
C，53.00，H，3.49，N，13.24
实测值：
C，52.77，H，3.29，N，13.00
与上述同样操作，由盐酸α-氨基-α-乙基-戊二酰亚胺和盐酸α-氨基-α-丙基-戊二酰亚胺可分别获得3-(3-硝基苯二甲酰亚氨基)-3-乙基哌啶-2，6-二酮和3-(3-硝基苯二甲酰亚氨基)-3-丙基哌啶-2，6-二酮。
实施例7
3-(3-氨基苯二甲酰亚氨基)-3-甲基哌啶-2，6-二酮
在温热条件下将3-(3-硝基苯二甲酰亚氨基)-3-甲基哌啶-2，6-二酮(0.5g，1.57mmol)溶于丙酮(250mL)中，然后冷却至室温，在氮气氛围中，在该溶液中加入10％Pd/C(0.1g)。接着在50psi氢气压力下，在帕尔仪器中进行氢化反应，历时4小时。用硅藻土过滤反应液，滤饼用丙酮(50mL)洗涤。真空浓缩滤液，获得黄色固体。将该黄色固体混合入乙酸乙酯(10mL)中，历时30分钟。过滤所得淤浆，干燥(60℃，＜1mm)，获得0.37g(82％)为黄色固体的3-(3-氨基苯二甲酰亚氨基)-3-甲基哌啶-2，6-二酮。
熔点：268-269℃
1H NMR(DMSO-d6)
δ10.98(s，1H)，7.44(dd，J＝7.1，7.3Hz，1H)，6.99(d，J＝8.4Hz，1H)，6.94(d，J＝6.9Hz，1H)，6.52(s，2H)，2.71-2.47(m，3H)，2.08-1.99(m，1H)，1.87(s，3H)
13C NMR(DMSO-d6)
δ172.48，172.18，169.51，168.06，146.55，135.58，131.80，121.51，110.56，108.30，58.29，29.25，28.63，21.00
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，5.62分钟(99.18％)
分析计算值(C14H13N3O4)：
C， 58.53， H， 4.56， N， 14.63
实测值：
C， 58.60， H， 4.41， N， 14.36
与上述同样操作，由3-(3-硝基苯二甲酰亚氨基)-3-乙基哌啶-2，6-二酮和3-(3-硝基苯二甲酰亚氨基)-3-丙基哌啶-2，6-二酮可分别获得3-(3-氨基苯二甲酰亚氨基)-3-乙基哌啶-2，6-二酮和3-(3-氨基苯二甲酰亚氨基)-3-丙基哌啶-2，6-二酮。
实施例8
2-溴甲基-3-硝基苯甲酸甲酯
使搅拌下的2-甲基-3-硝基苯甲酸甲酯(17.6g，87.1mmol)和N-溴琥珀酰亚胺(18.9g，105mmol)的四氯化碳(243mL)溶液加热微微回流过夜，用于加热的是100W的灯泡，它与反应容器的距离为2cm。18小时后，使反应液冷却至室温，并过滤。用水(2×120mL)和盐水(120mL)洗涤滤液后，用硫酸镁干燥，然后真空除去溶剂，用快速层析法精制(己烷∶乙酸乙酯＝8∶2)所得粗品，获得22g(93％)为黄色固体的2-溴甲基-3-硝基苯甲酸甲酯。
熔点：69-72℃
1H NMR(CDCl3)
δ8.13-8.09(dd，J＝3.6，7.86Hz，1H)，7.98-7.93(dd，J＝1.32，8.13Hz，1H)，7.57-7.51(t，J＝7.97Hz，1H)，5.16(s，2H)，4.0(s，3H)
13C NMR(CDCl3)
δ65.84，150.56，134.68，132.64，132.36，129.09，53.05，22.70
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，40/60CH3CN/0.1％H3PO4(aq)，8.2分钟99％
分析计算值(C9H8NO4Br)：
C， 39.44， H， 2.94， N， 5.11， Br， 29.15
实测值：
C， 39.51， H， 2.79， N， 5.02， Br， 29.32
实施例9
3-(1-氧-4-硝基异二氢吲哚-1-基)-3-甲基哌啶-2，6-二酮
在搅拌下的盐酸α-氨基-α-甲基戊二酰亚胺(2.5g，14.0mmol)和2-溴甲基-3-硝基苯甲酸甲酯(3.87g，14.0mmol)的二甲基甲酰胺(40mL)中加入三乙胺(3.14g，30.8mmol)，然后在氮气氛围中使反应液加热回流6小时，冷却后真空浓缩。接着，将所得固体混合入水(50mL)和二氯甲烷中，历时30分钟，过滤所得淤浆，固状物用二氯甲烷洗涤，并真空干燥(60℃，＜1mm)，获得2.68g(63％)为灰白色的3-(1-氧-4-硝基异二氢吲哚-1-基)-3-甲基哌啶-2，6-二酮。
熔点：233-235℃
1H NMR(DMSO-d6)
δ10.95(s，1H)，8.49-8.46(d，J＝8.15Hz，1H)，8.13-8.09(d，J＝7.43Hz，1H)，7.86-7.79(t，J＝7.83Hz，1H)，5.22-5.0(dd，J＝19.35，34.6Hz，2H)，2.77-2.49(m，3H)，2.0-1.94(m，1H)，1.74(S，3H)
13C NMR(DMSO-d6)
δ173.07，172.27，164.95，143.15，137.36，135.19，130.11，129.32，126.93，57.57，48.69，28.9，27.66，20.6
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，4.54分钟99.6％
分析计算值(C14H13N3O5)：
C， 55.45， H， 4.32， N， 13.86
实测值：
C， 52.16， H， 4.59， N， 12.47
用等当量的盐酸α-氨基-α-乙基戊二酰亚胺和盐酸α-氨基-α-丙基戊二酰亚胺代替盐酸α-氨基-α-甲基戊二酰亚胺可分别获得3-(1-氧-4-硝基异二氢吲哚-1-基)-3-乙基哌啶-2，6-二酮和3-(1-氧-4-硝基异二氢吲哚-1-基)-3-丙基哌啶-2，6-二酮。
实施例10
3-(1-氧-4-氨基异二氢吲哚-1-基)-3-甲基哌啶-2，6-二酮
在温热条件下将3-(1-氧-4-硝基异二氢吲哚-1-基)-3-甲基哌啶-2，6-二酮(1.0g，3.3mmol)溶于甲醇(500mL)中，并冷却至室温。然后，在氮气氛围中，在上述溶液中加入10％Pd/C(0.3g)。接着在50psi的氢气压力下，使上述反应液在帕尔仪器中进行加氢反应，历时4小时。然后用硅藻土过滤反应液，并用甲醇(50mL)洗涤硅藻土，真空浓缩滤液，获得灰白色固体。再将该固体混合入二氯甲烷(20mL)中，历时30分钟。过滤所得淤浆，并干燥所得固体(60℃，＜1mm)，获得0.54g(60％)为白色固体的3-(1-氧-4-氨基异二氢吲哚-1-基)-3-甲基哌啶-2，6-二酮。
熔点：268-270℃
1H NMR(DMSO-d6)
δ10.85(s，1H)，7.19-7.13(t，J＝7.63Hz，1H)，6.83-6.76(m，2H)，5.44(s，2H)，4.41(s，2H)，2.71-2.49(m，3H)，1.9-1.8(m，1H)，1.67(s，3H)
13C NMR(DMSO-d6)
δ173.7，172.49，168.0，143.5，132.88，128.78，125.62，116.12，109.92，56.98，46.22，29.04，27.77，20.82
HPLC：Waters Nova-Pak C18柱，4微米，1mL/min，240nm，20/80CH3CN/0.1％H3PO4(aq)，1.5分钟(99.6％)
分析计算值(C14H15N3O3)：
C， 61.53， H， 5.53， N， 15.38
实测值：
C， 58.99， H， 5.48， N， 14.29
由3-(1-氧-4-硝基异二氢吲哚-1-基)-3-乙基哌啶-2，6-二酮和3-(1-氧-4-硝基异二氢吲哚-1-基)-3-丙基哌啶-2，6-二酮可分别获得3-(1-氧-4-氨基异二氢吲哚-1-基)-3-乙基哌啶-2，6-二酮和3-(1-氧-4-氨基异二氢吲哚-1-基)-3-丙基哌啶-2，6-二酮。
实施例11
按照以下步骤能够获得每片含50mg 1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7-四氟异二氢吲哚的片剂。
组成(1000片)
1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7- 50.0g
四氟异二氢吲哚
乳糖 50.7g
麦淀粉 7.5g
聚乙二醇6000 5.0g
滑石粉 5.0g
硬脂酸镁 1.8g
软化水 q.s.
首先，使固体组分过孔径为0.6mm的筛子，然后混合活性组分、乳糖、滑石粉、硬脂酸镁和一半量的淀粉，另一半淀粉被悬浮在40mL水中，再将该悬浮液加入100mL沸腾的聚乙二醇水溶液中，接着，将所得的糊状物加入到粉末状物质中，并将混合物制成颗粒状，如有必要，还可添加水。然后在35℃的温度下彻夜干燥颗粒物，再过孔径为1.2mm的筛子整粒，最后压片，获得直径为6mm、且两边内凹的片剂。
实施例12
按照以下步骤能够获得每片含100mg 1-氧-2-(2，6-二氧哌啶-3-基)-4-氨基异二氢吲哚的片剂。
组成(1000片)
1-氧-2-(2，6-二氧哌啶-3-基)-4-氨基异二氢吲哚 100.0g
乳糖 100.0g
麦淀粉 47.0g
硬脂酸镁 3.0g
首先，使所有固体组分过孔径为0.6mm的筛子，然后混合活性组分、乳糖、硬脂酸镁和一半量的淀粉，另一半淀粉被悬浮在40mL水中，再将该悬浮液加入100mL沸腾的水中，接着，将所得的糊状物加入到粉末状物质中，并将混合物制为颗粒状，如有必要，还可添加水。然后在35℃的温度下彻夜干燥颗粒物，再通过孔径为1.2mm的筛子整粒，最后压片，获得直径为6mm、且两边内凹的片剂。
实施例13
按照以下步骤能够获得每片含有75mg 2-(2，6-二氧-3-甲基哌啶-3-基)-4-氨基邻苯二甲酰亚胺的咀嚼片剂。
组成(1000片)
2-(2，6-二氧-3-甲基哌啶-3-基)-4-氨基邻苯二甲酰亚胺 75.0g
甘露糖醇 230.0g
乳糖 150.0g
滑石粉 21.0g
甘氨酸 12.5g
硬脂酸 10.0g
糖精 1.5g
5％明胶溶液 q.s.首先，使所有固体组分过孔径为0.25mm的筛子，然后混合甘露糖醇和乳糖，并在其中加入明胶溶液，造粒，再通过孔径为2mm的筛子，并在50℃的温度下干燥，然后再通过孔径为1.7mm的筛子。接着，小心地混合2-(2，6-二氧-3-甲基哌啶-3-基)-4-氨基邻苯二甲酰亚胺、甘氨酸和糖精，再添加甘露糖醇、乳糖颗粒、硬脂酸和滑石粉，然后充分混合，压成直径为10mm、两边凹陷、上面有一个槽的片剂。
实施例14
按照以下步骤能够获得每片含10mg 2-(2，6-二氧乙基哌啶-3-基)-4-氨基邻苯二甲酰亚胺的片剂。
组成(1000片)
2-(2，6-二氧乙基哌啶-3-基)-4-氨基邻苯二甲酰亚胺 10.0g
乳糖 328.5g
玉米淀粉 17.5g
聚乙二醇6000 5.0g
滑石粉 25.0g
硬脂酸镁 4.0g
软化水 q.s.
首先，使所有固体组分通过孔径为0.6mm的筛子，然后充分混合酰亚胺活性组分、乳糖、滑石粉、硬脂酸镁和一半量的淀粉，另一半淀粉被悬浮在65mL水中，再将该悬浮液加入260mL沸腾的聚乙二醇水溶液中，接着，将所得的糊状物加入到粉末状物质中，并将混合物制成颗粒，如有必要，还可添加水。然后在35℃的温度下彻夜干燥颗粒物，再通过孔径为1.2mm的筛子整粒，最后压片，获得直径为10mm、两边内凹、且上面有一个槽的片剂。
实施例15
按照以下步骤能够获得每个胶囊含100mg 1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7-四氟异二氢吲哚的明胶干填胶囊剂。
组成(1000粒胶囊)
1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7- 100.0g
四氟异二氢吲哚
微晶纤维素 30.0g
十二烷基硫酸钠 2.0g
硬脂酸镁 8.0g
首先，使十二烷基硫酸钠通过孔径为0.2mm的筛子而添加入1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7-四氟异二氢吲哚中，充分混合10分钟后，再使微晶纤维素通过孔径为0.9mm的筛子而添加入上述混合物中，然后充分混合10分钟。接着，使硬脂酸镁通过孔径为0.8mm的筛子而添加入混合物中，再混合3分钟，最后将上述混合物(每个胶囊装入140mg)装入型号为0(拉长型)的明胶干填胶囊中。实施例16按照以下步骤能够获得0.2％注射剂或输液。
1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7- 5.0g
四氟异二氢吲哚
氯化钠 22.5g
pH7.4的磷酸缓冲液 300.0g
软化水 加到2500.0mL
首先将1-氧-2-(2，6-二氧-3-甲基哌啶-3-基)-4，5，6，7-四氟异二氢吲哚溶于1000mL水中，用微孔滤膜过滤后，添加缓冲液，然后加水使容量达到2500mL。最后将上述溶液装入玻璃安瓿(每个瓶装入1.0或2.5mL溶液，即分别含2.0或5.0mg酰亚胺)中。
Claims (12)
1. 2，6-二氧哌啶，选自以下物质：(a)下式表示的化合物，
其中，X和Y中一个是C＝O，X和Y中另一个是C＝O或CH2；
(i)R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，或(ii)R1、R2、R3和R4之一为-NHR5，其余的R1、R2、R3和R4为氢原子；
R5为氢原子或1-8个碳原子的烷基或CO-R7-CH(R10)NR8R9；
R6为氢原子、1-8个碳原子的烷基、苄基、氯原子或氟原子；
R7为间亚苯基或对亚苯基或-(CnH2n)-，其中的n为0-4；
R8和R9各自独立地为氢原子或1-8个碳原子的烷基，或者R8和R9一起表示四亚甲基、1，5-亚戊基、1，6-亚己基或-CH2CH2XCH2CH2-，其中的X为-O-、-S-或-NH-；
R10为氢原子、1-8个碳原子的烷基或苯基；
(b)含有一个可被质子化的氮原子的所述化合物的酸加成盐。
2.如权利要求1所述的化合物，其中R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，R6为氢原子、甲基、乙基或丙基，R7为间亚苯基或对亚苯基，R8和R9各自独立地为氢原子或甲基，R10为氢原子。
3.如权利要求1所述的化合物，其中R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，R6为氢原子、甲基、乙基或丙基，R7为-(CnH2n)-，其中的n为0-4，R8和R9各自独立地为氢原子或甲基，R10为氢原子。
4.如权利要求1所述的化合物，其中R1、R2、R3和R4之一为-NH2，其余的R1、R2、R3和R4为氢原子，R6为氢原子、甲基、乙基或丙基，R7为间亚苯基或对亚苯基，R8和R9各自独立地为氢原子或甲基，R10为氢原子。
5.如权利要求1所述的化合物，其中R1、R2、R3和R4之一为-NH2，其余的R1、R2、R3和R4为氢原子，R6为氢原子、甲基、乙基或丙基，R7为-(CnH2n)-，其中的n为0-4，R8和R9各自独立地为氢原子或甲基，R10为氢原子。
6. 2，6-二氧哌啶，选自以下物质：
(a)下式表示的化合物，
其中，X和Y中一个是C＝O，X和Y中另一个是C＝O或CH2；
(i)R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，或(ii)R1、R2、R3和R4之一为-NHR5，其余的R1、R2、R3和R4为氢原子；
R5为氢原子或1-8个碳原子的烷基或CO-R7-CH(R10)NR8R9；
R6为1-8个碳原子的烷基、苄基、氯原子或氟原子；
R7为间亚苯基或对亚苯基或-(CnH2n)-，其中的n为0-4；
R8和R9各自独立地为氢原子或1-8个碳原子的烷基，或者R8和R9一起表示四亚甲基、1，5-亚戊基、1，6-亚己基或-CH2CH2XCH2CH2-，其中的X为-O-、-S-或-NH-；
R10为氢原子、1-8个碳原子的烷基或苯基；
(b)含有一个可被质子化的氮原子的所述化合物的酸加成盐。
7.如权利要求6所述的化合物，其中R1、R2、R3和R4各自独立地为卤原子、1-4个碳原子的烷基或1-4个碳原子的烷氧基，R6为甲基、乙基或丙基。
8.如权利要求6所述的化合物，其中R1、R2、R3和R4之一为-NH2，其余的R1、R2、R3和R4为氢原子，R6为甲基、乙基或丙基。
9.降低哺乳动物所不希望有的TNFα水平的方法，其特征在于，对其施用有效量的权利要求1所述的化合物。
10.降低哺乳动物所不希望有的TNFα水平的方法，其特征在于，对其施用有效量的权利要求6所述的化合物。
11.药物组合物，包含其量按单次或多次剂量方案给药后足以降低哺乳动物TNFα水平的权利要求1所述的化合物及载体。
12.药物组合物，包含其量按单次或多次剂量方案给药后足以降低哺乳动物TNFα水平的权利要求6所述的化合物及载体。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4827897P | 1997-05-30 | 1997-05-30 | |
| US60/048,278 | 1997-05-30 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100525903A Division CN1680367A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－（2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
| CNA2006101262647A Division CN1911927A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1258293A true CN1258293A (zh) | 2000-06-28 |
Family
ID=21953674
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100525903A Pending CN1680367A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－（2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
| CNA2006101262647A Pending CN1911927A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
| CN98805614A Pending CN1258293A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100525903A Pending CN1680367A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－（2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
| CNA2006101262647A Pending CN1911927A (zh) | 1997-05-30 | 1998-05-28 | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6395754B1 (zh) |
| EP (3) | EP1956017B1 (zh) |
| JP (2) | JP4307567B2 (zh) |
| KR (1) | KR100526212B1 (zh) |
| CN (3) | CN1680367A (zh) |
| AT (2) | ATE401319T1 (zh) |
| AU (1) | AU741982B2 (zh) |
| CA (2) | CA2291218C (zh) |
| CY (1) | CY1108348T1 (zh) |
| CZ (1) | CZ299812B6 (zh) |
| DE (2) | DE69825994T2 (zh) |
| DK (2) | DK1486496T3 (zh) |
| ES (3) | ES2403102T3 (zh) |
| FI (1) | FI19992490A (zh) |
| HK (1) | HK1072248A1 (zh) |
| HU (2) | HU228769B1 (zh) |
| MC (1) | MC225A7 (zh) |
| NO (6) | NO322080B1 (zh) |
| NZ (1) | NZ501429A (zh) |
| PL (1) | PL193276B1 (zh) |
| PT (2) | PT1486496E (zh) |
| RU (1) | RU2209207C2 (zh) |
| SK (1) | SK163099A3 (zh) |
| TR (4) | TR200500299T2 (zh) |
| WO (1) | WO1998054170A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863878B (zh) * | 2003-09-04 | 2012-07-18 | 细胞基因公司 | 3-(4-氨基-1-氧代-1,3 二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物 |
| US9101620B2 (en) | 2009-11-02 | 2015-08-11 | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
Families Citing this family (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| ATE233753T1 (de) * | 1997-11-18 | 2003-03-15 | Celgene Corp | Substituierte 2-(2,6-dioxo-3-fluoropiperidin-3- yl)-isoindoline und ihre verwendung zur verminderung des tnfa spiegels |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| EP1064277B1 (en) * | 1998-03-16 | 2005-06-15 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| RU2001121987A (ru) | 1999-03-18 | 2004-02-27 | Селджин Корпорейшн (Us) | Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| DE60130799T2 (de) * | 2000-11-30 | 2008-07-17 | Children's Medical Center Corp., Boston | Synthese von 4-aminothalidomid enantiomeren |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7682803B2 (en) | 2005-10-13 | 2010-03-23 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| WO2003086373A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1505973B1 (en) | 2002-05-17 | 2010-03-03 | Celgene Corporation | Combinations for treating multiple myeloma |
| NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| KR20050056247A (ko) * | 2002-10-15 | 2005-06-14 | 셀진 코포레이션 | 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물 |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| CN101108185A (zh) * | 2002-10-24 | 2008-01-23 | 细胞基因公司 | 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物 |
| TWI310312B (en) * | 2002-10-31 | 2009-06-01 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| KR20090048520A (ko) | 2002-11-06 | 2009-05-13 | 셀진 코포레이션 | 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물 |
| CA2506442A1 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
| US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| OA13284A (en) * | 2003-11-06 | 2007-01-31 | Corporation Celgene | Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases. |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20060004043A1 (en) | 2003-11-19 | 2006-01-05 | Bhagwat Shripad S | Indazole compounds and methods of use thereof |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| NZ550026A (en) * | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
| US20080199422A1 (en) * | 2004-04-14 | 2008-08-21 | Celgene Corporation | Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline |
| CA2563810A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| CA2565447A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
| CA2579291C (en) * | 2004-09-03 | 2011-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| BRPI0518062A (pt) * | 2004-10-28 | 2008-10-28 | Celgene Corp | uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
| CA2588597A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| ZA200707010B (en) * | 2005-01-25 | 2009-01-28 | Celgene Corp | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidini-3-yl)-isoindole-1-3-dione |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| JP5366544B2 (ja) * | 2005-06-30 | 2013-12-11 | セルジーン コーポレイション | ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法 |
| KR20080026198A (ko) * | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원 |
| WO2007009061A2 (en) * | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
| EP1919500A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| ES2434946T3 (es) | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
| US8715677B2 (en) | 2005-09-01 | 2014-05-06 | Celgene Corporation | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
| US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| WO2008021391A1 (en) | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ES2426350T3 (es) * | 2006-08-30 | 2013-10-22 | Celgene Corporation | Compuestos de isoindolina sustituidos en 5 |
| RU2448101C2 (ru) * | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| DK2420497T3 (en) | 2006-09-26 | 2016-03-07 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
| US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
| JP5769925B2 (ja) | 2006-10-06 | 2015-08-26 | アントフロゲネシス コーポレーション | ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法 |
| CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| EP2630959A1 (en) | 2007-02-12 | 2013-08-28 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
| WO2008100497A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
| US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
| KR20210127819A (ko) | 2007-09-28 | 2021-10-22 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
| US7964354B2 (en) | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
| WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| NZ592425A (en) * | 2008-10-29 | 2013-04-26 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
| WO2010093434A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of lenalidomide |
| AU2010229711B2 (en) | 2009-03-25 | 2015-06-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| CN102448472A (zh) | 2009-05-25 | 2012-05-09 | 国立大学法人东京工业大学 | 包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物 |
| BR112012015129A2 (pt) | 2009-12-22 | 2019-09-24 | Celgene Corp | "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio" |
| MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
| RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
| US9408831B2 (en) | 2010-04-07 | 2016-08-09 | Celgene Corporation | Methods for treating respiratory viral infection |
| US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
| WO2012096884A1 (en) | 2011-01-10 | 2012-07-19 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
| TWI601722B (zh) | 2011-03-11 | 2017-10-11 | 西建公司 | ３-（５-胺基-２-甲基-４-氧基-４ｈ-喹唑啉-３-基）-六氫吡啶-２，６-二酮之固體型式及其醫藥組合物及用途 |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012145309A1 (en) | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| US9365640B2 (en) | 2011-04-29 | 2016-06-14 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2707579T3 (es) | 2011-06-01 | 2019-04-04 | Celularity Inc | Tratamiento del dolor usando citoblastos placentarios |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| JP2014526508A (ja) | 2011-09-14 | 2014-10-06 | セルジーン コーポレイション | シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤 |
| KR102035362B1 (ko) | 2011-12-27 | 2019-10-22 | 셀진 코포레이션 | (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 |
| US10335482B2 (en) | 2012-06-06 | 2019-07-02 | Bionor Immuno As | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer |
| JP6318152B2 (ja) | 2012-06-29 | 2018-04-25 | セルジーン コーポレイション | セレブロン関連タンパク質を利用して薬物効能を決定する方法 |
| US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| MX359508B (es) | 2012-08-09 | 2018-09-28 | Celgene Corp | Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2,6-diona y composiciones que comprenden y metodos para utilizar las mismas. |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| US9694015B2 (en) | 2012-09-10 | 2017-07-04 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| JP2016506968A (ja) | 2013-02-05 | 2016-03-07 | アントフロゲネシス コーポレーション | 胎盤由来のナチュラルキラー細胞 |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| KR102382576B1 (ko) | 2013-04-17 | 2022-04-08 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법 |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
| PL3214081T3 (pl) | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
| EP3313818B1 (en) | 2015-06-26 | 2023-11-08 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| ITUB20169994A1 (it) | 2016-01-14 | 2017-07-14 | Phf Sa | Nuove forme cristalline di farmaci immunomodulatori |
| CA3045508A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
| EP4327878A3 (en) | 2017-05-01 | 2024-05-01 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| BR112019025403A2 (pt) | 2017-06-02 | 2020-08-18 | Juno Therapeutics Inc | artigos de fabricação e métodos para tratamento usando terapia celular adotiva |
| JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
| US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
| SG11202007495SA (en) | 2018-02-21 | 2020-09-29 | Celgene Corp | Bcma-binding antibodies and uses thereof |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| EP3876958A1 (en) | 2018-11-08 | 2021-09-15 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| WO2020102195A1 (en) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| US20220008465A1 (en) | 2018-11-16 | 2022-01-13 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| SG11202105502RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for treatment using adoptive cell therapy |
| TWI820276B (zh) | 2018-12-19 | 2023-11-01 | 美商西建公司 | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE39483T1 (de) * | 1982-04-02 | 1989-01-15 | Takeda Chemical Industries Ltd | Kondensierte pyrrolinon-derivate, und ihre herstellung. |
| US4849441A (en) * | 1986-12-25 | 1989-07-18 | Kyowa Hakko Kogyo Co., Ltd. | Isoindolin-1-one derivative and antiarrhythmic agent |
| US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
| EP0580641B1 (de) * | 1991-04-17 | 1996-12-27 | Grünenthal GmbH | Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| DE4422237A1 (de) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
| US5795368A (en) * | 1996-03-01 | 1998-08-18 | O.I. Corporation | Microtrap sample concentrator and methods of use |
| DE19613976C1 (de) * | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| EP0925294B3 (en) * | 1996-07-24 | 2018-07-04 | Celgene Corporation | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
| KR100539030B1 (ko) * | 1996-08-12 | 2005-12-27 | 셀진 코포레이션 | 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법 |
| JP2002513391A (ja) * | 1996-11-05 | 2002-05-08 | ザ チルドレンズ メディカル センター コーポレイション | 血管形成の抑制のための方法と組成物 |
| US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| EP1064277B1 (en) * | 1998-03-16 | 2005-06-15 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
| WO2000055139A2 (en) * | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| RU2001121987A (ru) * | 1999-03-18 | 2004-02-27 | Селджин Корпорейшн (Us) | Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| CN1420776A (zh) * | 2000-03-31 | 2003-05-28 | 塞尔基因公司 | 环氧合酶－2活性的抑制 |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| DE60130799T2 (de) | 2000-11-30 | 2008-07-17 | Children's Medical Center Corp., Boston | Synthese von 4-aminothalidomid enantiomeren |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US7320991B2 (en) * | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| AU2002323063B2 (en) * | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| WO2003086373A1 (en) | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1505973B1 (en) | 2002-05-17 | 2010-03-03 | Celgene Corporation | Combinations for treating multiple myeloma |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| CN101108185A (zh) | 2002-10-24 | 2008-01-23 | 细胞基因公司 | 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物 |
| US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| TWI310312B (en) | 2002-10-31 | 2009-06-01 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| EP1694328A4 (en) * | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| NZ550026A (en) * | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US20080199422A1 (en) | 2004-04-14 | 2008-08-21 | Celgene Corporation | Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline |
| CA2563810A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| CA2565447A1 (en) | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
-
1997
- 1997-07-24 HU HU9903929A patent/HU228769B1/hu active Protection Beyond IP Right Term
-
1998
- 1998-05-28 KR KR10-1999-7011076A patent/KR100526212B1/ko not_active IP Right Cessation
- 1998-05-28 CZ CZ0427899A patent/CZ299812B6/cs not_active IP Right Cessation
- 1998-05-28 AT AT04077432T patent/ATE401319T1/de active
- 1998-05-28 DK DK04077432T patent/DK1486496T3/da active
- 1998-05-28 PT PT04077432T patent/PT1486496E/pt unknown
- 1998-05-28 TR TR200500299T patent/TR200500299T2/xx unknown
- 1998-05-28 TR TR200801878T patent/TR200801878T2/xx unknown
- 1998-05-28 DE DE1998625994 patent/DE69825994T2/de not_active Expired - Lifetime
- 1998-05-28 ES ES08009864T patent/ES2403102T3/es not_active Expired - Lifetime
- 1998-05-28 DE DE69839739T patent/DE69839739D1/de not_active Expired - Lifetime
- 1998-05-28 CA CA 2291218 patent/CA2291218C/en not_active Expired - Fee Related
- 1998-05-28 PL PL337124A patent/PL193276B1/pl unknown
- 1998-05-28 CN CNA2005100525903A patent/CN1680367A/zh active Pending
- 1998-05-28 AU AU77012/98A patent/AU741982B2/en not_active Ceased
- 1998-05-28 ES ES04077432T patent/ES2309443T3/es not_active Expired - Lifetime
- 1998-05-28 CA CA 2669481 patent/CA2669481C/en not_active Expired - Fee Related
- 1998-05-28 TR TR201005282T patent/TR201005282T2/xx unknown
- 1998-05-28 US US09/445,002 patent/US6395754B1/en not_active Expired - Lifetime
- 1998-05-28 TR TR200000107T patent/TR200000107T2/xx unknown
- 1998-05-28 WO PCT/US1998/010886 patent/WO1998054170A1/en active Application Filing
- 1998-05-28 EP EP20080009864 patent/EP1956017B1/en not_active Expired - Lifetime
- 1998-05-28 HU HU0003217A patent/HU229578B1/hu not_active IP Right Cessation
- 1998-05-28 PT PT98924959T patent/PT984955E/pt unknown
- 1998-05-28 ES ES98924959T patent/ES2229497T3/es not_active Expired - Lifetime
- 1998-05-28 CN CNA2006101262647A patent/CN1911927A/zh active Pending
- 1998-05-28 AT AT98924959T patent/ATE275139T1/de active
- 1998-05-28 RU RU99128073A patent/RU2209207C2/ru not_active IP Right Cessation
- 1998-05-28 DK DK98924959T patent/DK0984955T3/da active
- 1998-05-28 SK SK1630-99A patent/SK163099A3/sk unknown
- 1998-05-28 JP JP50090999A patent/JP4307567B2/ja not_active Expired - Fee Related
- 1998-05-28 EP EP19980924959 patent/EP0984955B1/en not_active Expired - Lifetime
- 1998-05-28 NZ NZ501429A patent/NZ501429A/en not_active IP Right Cessation
- 1998-05-28 CN CN98805614A patent/CN1258293A/zh active Pending
- 1998-05-28 EP EP20040077432 patent/EP1486496B1/en not_active Expired - Lifetime
-
1999
- 1999-11-23 FI FI992490A patent/FI19992490A/fi unknown
- 1999-11-23 NO NO19995751A patent/NO322080B1/no not_active IP Right Cessation
-
2002
- 2002-05-10 US US10/143,416 patent/US20020173658A1/en not_active Abandoned
-
2005
- 2005-01-14 US US11/035,817 patent/US7459466B2/en not_active Expired - Fee Related
- 2005-03-08 HK HK05102027A patent/HK1072248A1/xx not_active IP Right Cessation
- 2005-08-11 MC MC225K patent/MC225A7/xx unknown
-
2006
- 2006-03-30 NO NO20061455A patent/NO331367B1/no not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY081101005T patent/CY1108348T1/el unknown
-
2009
- 2009-02-06 JP JP2009025981A patent/JP2009138009A/ja active Pending
- 2009-08-18 NO NO20092860A patent/NO332270B1/no not_active IP Right Cessation
-
2011
- 2011-11-08 NO NO20111536A patent/NO332271B1/no not_active IP Right Cessation
-
2012
- 2012-03-06 NO NO2012004C patent/NO2012004I2/no unknown
- 2012-03-20 NO NO20120330A patent/NO333641B1/no not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863878B (zh) * | 2003-09-04 | 2012-07-18 | 细胞基因公司 | 3-(4-氨基-1-氧代-1,3 二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物 |
| US9101620B2 (en) | 2009-11-02 | 2015-08-11 | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. | Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1258293A (zh) | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法 | |
| CN1271067C (zh) | 取代的2－(2,6－二氧－3－氟哌啶－3－基)－异二氢吲哚及其降低肿瘤坏死因子α水平的用途 | |
| CN1290501C (zh) | 有药学活性的异吲哚啉衍生物 | |
| CN100390163C (zh) | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 | |
| CN1117089C (zh) | 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法 | |
| CN1092640C (zh) | 作为磷酸二酯酶ⅲ、ⅳ和tnf抑制剂的亚酰胺 | |
| CN1254333A (zh) | 新的免疫治疗剂亚酰胺/酰胺类 | |
| CN1413109A (zh) | 取代的酰基异羟肟酸和降低TNF－α水平的方法 | |
| CN1413211A (zh) | 取代的1,3,4－氧二氮茂及降低TNF－α水平的方法 | |
| CN1342146A (zh) | 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途 | |
| EP1308444B1 (en) | Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha Levels | |
| AU2005239663B2 (en) | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-YL)-isoindolines and their use to reduce TNFalpha levels | |
| AU2002320734B2 (en) | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce TNFalpha levels | |
| MXPA99010998A (es) | 2-(2,6-dioxopiperidin-3-il)ftalamidas y 1-oxoisoindolinas sustituidas y metodo para reducir niveles tnf alfa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1029110 Country of ref document: HK |